Montanova Capital LLC raised its position in Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) by 64.8% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,206,217 shares of the company's stock after acquiring an additional 2,833,333 shares during the quarter. Montanova Capital LLC owned approximately 6.95% of Aura Biosciences worth $51,164,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Legal & General Group Plc bought a new stake in Aura Biosciences in the second quarter valued at approximately $29,000. Parallel Advisors LLC raised its stake in Aura Biosciences by 130.4% in the 1st quarter. Parallel Advisors LLC now owns 5,665 shares of the company's stock valued at $38,000 after acquiring an additional 3,206 shares during the period. Tower Research Capital LLC TRC raised its stake in Aura Biosciences by 49.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company's stock valued at $40,000 after acquiring an additional 2,104 shares during the period. ProShare Advisors LLC acquired a new stake in Aura Biosciences during the 4th quarter valued at $59,000. Finally, Water Island Capital LLC acquired a new stake in Aura Biosciences during the 3rd quarter valued at $64,000. Institutional investors own 96.75% of the company's stock.
Insider Activity
In other news, insider Anthony S. Gibney sold 12,824 shares of the business's stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $6.42, for a total value of $82,330.08. Following the completion of the sale, the insider owned 265,354 shares of the company's stock, valued at approximately $1,703,572.68. The trade was a 4.61% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 1.90% of the company's stock.
Aura Biosciences Trading Down 3.0%
NASDAQ:AURA opened at $7.18 on Tuesday. The stock has a market cap of $744.64 million, a P/E ratio of -4.10 and a beta of 0.40. The stock has a 50 day simple moving average of $7.31 and a 200 day simple moving average of $6.91. Aura Biosciences, Inc. has a 1-year low of $4.73 and a 1-year high of $9.53.
Aura Biosciences (NASDAQ:AURA - Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.48) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.10). As a group, sell-side analysts forecast that Aura Biosciences, Inc. will post -1.61 EPS for the current year.
Analyst Ratings Changes
Several equities analysts have commented on the stock. Wall Street Zen downgraded shares of Aura Biosciences from a "hold" rating to a "sell" rating in a report on Sunday, August 16th. Weiss Ratings upgraded shares of Aura Biosciences from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, July 14th. Leerink Partners set a $17.00 target price on shares of Aura Biosciences in a report on Tuesday, May 12th. Finally, HC Wainwright decreased their price target on shares of Aura Biosciences from $24.00 to $18.00 and set a "buy" rating on the stock in a research note on Tuesday, August 11th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Aura Biosciences has an average rating of "Hold" and a consensus target price of $17.50.
Read Our Latest Stock Analysis on Aura Biosciences
Aura Biosciences Profile
(
Free Report)
Aura Biosciences is a clinical‐stage biopharmaceutical company focused on the development of novel virus‐like particle (VLP) therapies for the treatment of cancer. By combining proprietary VLP technology with photoactivatable dyes, Aura aims to deliver highly selective photodynamic therapies that target and destroy tumor cells while sparing healthy tissue. The company's platform is designed to address solid tumors in both ophthalmic and non‐ophthalmic settings, leveraging precision activation via near‐infrared light to induce localized tumor cell apoptosis and stimulate anti‐tumor immune responses.
The lead product candidate, AU-011, is being evaluated in patients with choroidal melanoma, a rare but potentially sight-threatening eye cancer.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Aura Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aura Biosciences wasn't on the list.
While Aura Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
